AbbVie stock moves down with RSI signaling oversold conditions near $204: weekly analysis

Traders Union
All News
Financial News
AbbVie slides 1.75% this week

Highlights

AbbVie is experiencing persistent bearish momentum, trading below key moving averages after a 1.75% weekly decline.
Momentum indicators confirm strong selling pressure, with oversold signals and no evidence of bullish divergence.
Next week, AbbVie is likely to remain range-bound between $194.11 and $203.66, with a higher probability of testing downside support.

Dividend hike and Humira discount reshape sentiment as flows diverge

AbbVie increased its dividend by 5.5% for 2026, maintaining its status as a leading high-yield stock with a current yield near 3.3%. The company confirmed that it will offer its flagship immunology drug Humira at a significant discount through the government’s new TrumpRx platform, potentially reshaping its future revenue mix. Institutional flows were mixed, as SageGuard Financial Group LLC acquired new shares and PFG Advisors reduced its holdings, while AbbVie marked a milestone in its neurology pipeline with Nxera Pharma.

Extended bearish momentum as indicators warn of oversold conditions

On the weekly timeframe, technical indicators reveal persistent bearish pressure. AbbVie trades firmly below both the 20- and 50-week moving averages, while staying comfortably above the 200-week MA. Weekly momentum is negative, with the MACD remaining in the sell zone, RSI at 40.59, and both the Stochastic RSI and Commodity Channel Index signaling oversold conditions. Sellers are in control, as shown by strong Bear Power readings, and the stock continues to trade in the lower part of its recent weekly range with volatility at 5.66%. Key weekly support is at $194.11, while resistance lies near $203.66, with additional overhead resistance at the MA-50.

Downside risk persists during week as rebound hinges on resistance reclaim

Over the next 5 trading days, AbbVie is likely to stay within a sideways corridor between $194.11 and $203.66, with a bias towards further downside as weekly indicators remain bearish. If the stock manages to reclaim the MA-50, a rebound could carry it to the $208–$210 range, but there is less than a 20% probability of such an upward move. The base case is for the stock to test the lower end of its current range. Should weakness persist, a move toward $194 is likely, challenging short-term support.

Anton Kharitonov, analyst at Traders Union, notes that AbbVie saw continued selling pressure this week, with the price dropping 1.75% to $204.72 and remaining under both the weekly MA-20 and MA-50. The persistent bearish momentum is confirmed by weak technical indicators and a negative shift in weekly sentiment, even as the stock stays above its MA-200 and maintains a solid dividend profile. He believes institutional flows were mixed and news around Humira’s discounted pricing could increase future volatility. Resistance at $203.66 continues to cap gains, while key support is found at $194.11, suggesting sellers remain in control. The outlook for the coming week points toward testing the lower end of the range unless the MA-50 is reclaimed decisively. "As long as AbbVie remains below the 50-week moving average, I see no catalyst for sustainable upside this week — the defensive bias is warranted."

Earlier, analysts noted that AbbVie remained under sustained selling pressure, with the stock consolidating amid a lack of positive technical momentum. The current analysis confirms this persistent bearish bias and highlights that a breakdown below the $194 short-term support could trigger further downside, making this level critical for near-term positioning.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.